Satoh Kennichi
Division of Gastroenterology, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi 983-8536, Japan.
Diagnostics (Basel). 2021 Feb 22;11(2):375. doi: 10.3390/diagnostics11020375.
Pancreatic ductal adenocarcinoma (PDAC) is the most malignant form of gastrointestinal tumor and is the fourth leading cause of deaths due to cancer in Japan. This cancer shows a poor outcome due to the difficulty of its early diagnosis and its rapid growth. Once this disease becomes clinically evident, it is frequently accompanied by distant metastasis at the time of diagnosis. A recent multicenter study in Japan revealed that patients with the early stage of this disease (stage 0 and I) showed favorable prognosis after surgical resection, indicating the importance of early detection for improvement of PDAC prognosis. PDAC develops through a stepwise progression from the precursor lesion, and over the last few decades molecular analyses have shown the detailed genetic alterations that occur in this process. Since advances in molecular technologies have enabled the detection of genetic changes from a very small quantity of samples, a large number of non-invasive molecular approaches have been utilized in an attempt to find precursor or non-invasive carcinoma lesions. In this review, the current efforts in terms of the molecular approaches applied for the early detection of PDAC-especially using body fluids such as pancreatic juice, blood, and saliva-are summarized.
胰腺导管腺癌(PDAC)是胃肠道肿瘤中恶性程度最高的类型,在日本是癌症死亡的第四大主要原因。由于早期诊断困难且生长迅速,这种癌症的预后较差。一旦该病在临床上变得明显,在诊断时常常伴有远处转移。日本最近的一项多中心研究表明,处于该病早期阶段(0期和I期)的患者在手术切除后显示出良好的预后,这表明早期检测对于改善PDAC预后的重要性。PDAC是从前体病变逐步发展而来的,在过去几十年中,分子分析已经揭示了这一过程中发生的详细基因改变。由于分子技术的进步使得能够从极少量样本中检测到基因变化,大量非侵入性分子方法已被用于试图找到前体或非侵入性癌病变。在这篇综述中,总结了目前在应用分子方法早期检测PDAC方面所做的努力,特别是使用胰液、血液和唾液等体液进行检测的方法。